Regarding fertility services, some women more equal than others

Researchers from the University of San Francisco have published the results of a survey in the journal Cancer that indicates that when it comes to getting fertility counseling among women with cancer, not all patients are treated equally.

The researchers sent out a survey to 2,500 women who had received a cancer diagnosis between 1993 and 2007. It asked them whether counseling regarding the risk of cancer treatment to their fertility had been offered to them prior to treatment, and whether they pursued such preservation services.

They heard back from 1,041 women, also taking note of several sociodemographic characteristics such as income, ethnicity, education, and age at diagnosis, among others. Their findings:

- Women with college degrees were more likely to receive fertility counseling
- Women who earn more than $30,000 annually were more likely to receive fertility counseling than women who reported lower incomes.
- Women over age 35 were less likely to receive fertility counseling than women between 18 and 25.

The only bright spot was that counseling and preservation services have increased over time.

Source: MedPageToday

More Articles

More Articles

Amazon.com is pleased to have the Lymphoma Information Network in the family of Amazon.com associates. We've agreed to ship items...

The question ought to be what are myelodysplastic syndromes (MDS), since this is a group of similar blood and bone marrow diseases that...

Merkel Cell Carcinoma (MCC) is a very rare and aggressive skin cancer that usually develops when a person is in his or her 70s. It is...

Radiation Therapy Topics

...

At some point, the Seattle biotech company Cell Therapeutics Inc (CTI) should earn an entry in the Guinness Book of World Records for utter and...

Site Beginnings

This site was started as Lymphoma Resource Page(s) in 1994. The site was designed to collect lymphoma...

Three papers appearing in the journal Blood and pointing towards a regulator-suppressor pill could offer hope to blood cancer...

The US Food and Drug Administration (FDA) has granted a third so-called Breakthrough Therapy Designation for the investigational oral...

The US Food and Drug Administration today has approved an expanded use of Imbruvica (ibrutinib) in patients with...

The U.S. Food and Drug Administration has announced that it has granted "Breakthrough Therapy Designation" for the investigational agent...

According to a new study published in the Proceedings of the National Academy of Sciences, a team from the University of California, San...

Pharmacyclics has announced that the company has submitted a New Drug Application (NDA) to the US Food and Drug Administration (FDA) for...

New research suggests that frontline radioimmunotherapy...

Gilead Sciences has announced results of the company's Phase II study of its investigational compound idelalisib, an oral inhibitor of...

Sitemap